Reuters:A new understanding of the link between diabetes and obesity may help drug companies design safer versions of treatments like GlaxoSmithKline's Avandia, U.S. researchers said on Wednesday.
The researchers had believed Avandia and Takeda Pharmaceutical Co's Actos work by stimulating a protein known as PPAR-gamma. Now the team thinks the drugs also act on the insulin resistance that diabetics develop through a different route...continue
Posts
No comments:
Post a Comment